Skip to Main Content
Table 2.

Clinical course of individual patients

PatientAfter stopping erlotinib or gefitinibAfter resuming erlotinib or gefitinib
No change No change 
Increased cough Cough stable 
Seizure, increase in size of brain mets Brain mets stable 
No change No change 
Increased cough Cough stable 
Increased pleural effusion Improved* 
No change No change 
Cough/fever Resolution 
Increased pain Pain stabilized 
10 Increased cough, hemoptysis Improved cough and hemoptysis 
11 Liver failure Death 
12 Pain/weakness No change 
13 Increased fatigue/weakness Increased pain 
PatientAfter stopping erlotinib or gefitinibAfter resuming erlotinib or gefitinib
No change No change 
Increased cough Cough stable 
Seizure, increase in size of brain mets Brain mets stable 
No change No change 
Increased cough Cough stable 
Increased pleural effusion Improved* 
No change No change 
Cough/fever Resolution 
Increased pain Pain stabilized 
10 Increased cough, hemoptysis Improved cough and hemoptysis 
11 Liver failure Death 
12 Pain/weakness No change 
13 Increased fatigue/weakness Increased pain 
*

Required drainage of pleural effusion before resumption of gefitinib.

Came off study before completing the first four CT and PET/CT scans.

Close Modal

or Create an Account

Close Modal
Close Modal